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syndrome but not of stable angina pectoris
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Qiutang Zeng3, Chao Chang1, Meng Chai1 and Yujie Zhou1*Abstract
Background: Recent evidence demonstrated that the circulating adipokines were associated with the onset of
acute coronary syndrome (ACS) including unstable angina pectoris (UAP) and acute myocardial infarction (AMI). As
a novel adipokine, chemerin has been related to atherosclerosis and the presence of coronary artery disease.
However, the plasma levels of chemerin in patients with ACS have yet to be investigated.
Methods: Plasma levels of chemerin and adiponectin were measured by an enzyme-linked immunosorbent assay
(ELISA) in 60 patients with stable angina pectoris (SAP), 60 patients with UAP, 60 patients with AMI and 40 control
patients. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured
using a GE ViVid E7 ultrasonography machine, and the severity of coronary stenosis in patients was estimated with
a Gensini coronary score following coronary angiography.
Results: Plasma chemerin levels were significantly higher in ACS patients than in the control and SAP groups, while
plasma adiponectin levels were significantly lower in ACS patients than the control group. A correlation analysis
revealed that plasma chemerin levels were positively correlated with the levels of C-reactive protein (CRP) (r = 0.29,
P < 0.01) and LVEDD (r = 0.27, P < 0.01) but negatively correlated with LVEF (r = -0.45, P < 0.01) and that plasma
adiponectin levels were positively correlated with LVEF (r = 0.53, P < 0.01) but negatively correlated with CRP
(r = -0.33, P < 0.01) and LVEDD (r = -0.30, P < 0.01). Although significant correlations between chemerin, adiponectin
and BMI or the Gensini coronary score were found in patients with SAP, neither chemerin nor adiponectin was
correlated with BMI and the Gensini coronary score in patients with ACS. Furthermore, both chemerin (OR 1.103,
95% CI 1.065 to 1.142; P = 0.001) and adiponectin (OR 0.871, 95% CI 0.776 to 0.970; P = 0.018) were independently
associated with the presence of ACS.
Conclusions: Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris.
Keywords: Chemerin, Adiponectin, Acute coronary syndrome, Inflammation, Left ventricular functionBackground
Coronary artery disease (CAD) is typically divided into
different clinical types including stable angina pectoris
(SAP) and acute coronary syndrome (ACS). ACS includ-
ing unstable angina pectoris (UAP) and acute myocardial
infarction (AMI) is the clinical definition of the critical
phase of CAD which results primarily from a disruption* Correspondence: azzyj12@163.com
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unless otherwise stated.of a coronary atherosclerotic plaque associated with par-
tial or complete thrombotic vessel occlusion [1-4]. In
contrast, SAP is the initial manifestation of ischemic
heart disease in one half of patients and becomes a recur-
rent symptom in survivors of ACS that is generally due to
one or more significant obstructive but more stable lesions
in coronary arteries [1-4]. Although chronic inflammation
is a characteristic shared between ACS and SAP, the in-
flammatory response is significantly more robust in ACS
than in SAP [1-4]. In addition, the prognosis for ACS is
poorer than for SAP, and revascularization therapy has to
be performed promptly in ACS but deliberately in thosehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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therapy or were performed by appropriate intracoronary
assessment of hemodynamic relevance. Therefore, it is ne-
cessary and helpful to seek biomarkers associated with the
presence of ACS.
Adipose tissue serves not only as a mass of fat for stor-
ing energy but also as an active endocrine organ that se-
cretes various bioactive adipokines. Most adipokines,
such as tumor necrosis factor (TNF)-α, interleukin (IL)-
6, visfatin and leptin are well-known pro-inflammatory
cytokines that accelerate atherosclerosis in experimental
model [5-10], and contribute to the presence of ACS
[11-14]. Other members of this group, such as adiponec-
tin, are anti-inflammatory cytokines that play a protect-
ive role in atherosclerosis [15], and the relationships
between the blood concentrations of this molecule and
ACS have been examined extensively [16-21]. The re-
sults from our and others studies showed circulating adi-
ponectin concentrations were significantly decreased in
ACS compared to the control and SAP groups, suggest-
ing that adiponectin is a biomarker of ACS [16-22]. In
addition, some studies demonstrated that circulating adi-
ponectin is significantly associated with the onset of cor-
onary artery disease and myocardial infarction in subjects
below the age of 60 [23,24], and all cause/cardio-vascular
disease (CVD) mortality [25].
Chemerin, which is also known as tazarotene-induced
gene 2 protein (TIG2) or retinoid acid receptor re-
sponder 2 (RARRES2), is a novel adipokine that plays a
pivotal role in adipose differentiation, maturation and
metabolism, regulation of immune response and insulin
resistance [26-29]. In addition, chemerin acts as an inflam-
matory mediator to promote the migration of macro-
phages and immature dendritic cells and the production
of pro-inflammatory cytokines. However, chemerin was
also demonstrated to play an anti-inflammatory role as
chemerin significantly prevented TNF-a-induced VCAM-
1 expression and monocyte adhesion by inhibiting the
activation of NF-КB and p38 in vitro [30]. Accumulating
evidence demonstrates that high concentrations of circu-
lating chemerin are associated with the presence of CAD,
suggesting that circulating chemerin is a novel biomarker
of CAD [31-34]. However, whether circulating chemerin
levels are different in patients with SAP and patients with
ACS has yet to be investigated.
In the present study, plasma levels of chemerin and
adiponectin were measured in enrolled patients with
SAP and ACS and the relationships between plasma
levels of these two adipokines and other clinical parame-
ters including were analyzed. Because previous studies
showed that medication use such as statin regulates the
secretion of adipokines [17], we also investigate the ef-
fects of medication use on plasma levels of chemerin
and adiponectin.Methods
Patients
We recruited 220 patients who underwent diagnostic cor-
onary angiography between Augest 2012 and March 2013
in Beijing Anzhen Hospital, the People’s Hospital of
Guangxi Zhuang Autonomous Region, and Union Hos-
pital, China. The patients were classified into 4 groups: (1)
Stable angina pectoris (SAP). The inclusion criteria for this
group were typical exertional chest discomfort that was as-
sociated with down sloping or horizontal ST-segment de-
pression >1 mm in an exercise test); (2) Unstable angina
pectoris (UAP). The inclusion criteria for this group were
chest pain at rest with definite ischemic electrocardio-
graphic changes: ST-segment changes and/or T-wave inver-
sions; (3) Acute myocardial infarction (AMI). The inclusion
criteria for this group were myocardial infarction that was
confirmed by a significant increase of troponin I and Creat-
ine Kinase MB levels; and (4) Control group, which con-
sisted of 40 subjects with normal coronary artery findings.
Written informed consent was obtained from each pa-
tient. The study was approved by the Ethics Committee of
Beijing Anzhen Hospital, the People’s Hospital of Guangxi
Zhuang Autonomous Region, and Union Hospital.
Patients with valvular heart disease, thromboembolism,
collagen disease, disseminated intravascular coagulation,
advanced liver disease, renal failure, malignant disease,
septicemia, other inflammatory disease, or current steroid
therapy were excluded from the study.
Clinical data collection
Clinical data were obtained upon admission to hospital.
Demographic data, height, body weight, medical history,
and medication use were recorded. Body mass index
(BMI) was calculated as weight (kg) divided by square of
height (m2).
Blood samples measurements
In the AMI group, blood samples were obtained from the
patients upon arrival at the emergency unit. Fasting blood
samples were obtained the morning after admission for
the rest of the study groups. The samples were collected
in sodium heparin Vacutainers (Becton-Dickinson). Blood
was centrifuged for 15 min at 3,000 × g and the plasma
was stored at -80°C until further use.
The levels of plasma chemerin and adiponectin (R&D
Systems, USA) were measured by an enzyme-linked im-
munosorbent assay (ELISA), following the manufacturer’s
instructions. The ELISA intra-assay and inter-assay coeffi-
cients of variation were <5% and <10%, respectively. All of
the samples were measured in duplicate.
The levels of lipid and lipoprotein fractions, fasting glu-
cose, creatinine and C-reactive protein (CRP) at baseline
were measured in central laboratory of Beijing Anzhen
Hospital.
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The patients underwent M-mode and 2D-echocardiography
using a GE ViVid E7 ultrasonography machine (GE
Healthcare, America) with a transthoracic 1.5–4.3 MHz
probe (M5S-D). Left ventricular end-diastolic diameter
(LVEDD) and fractional shortening were measured. Left
ventricular ejection fraction (LVEF) was calculated from
apical four chambers position by the area–length method.
Gensini score
The severity of coronary stenosis in patients was esti-
mated with a Gensini coronary score following coronary
angiography [35].
Statistical analysis
All of the data were given as the mean ± SD. When com-
paring only 2 groups, Student’s T-test was used. For com-
parisons involving 3 or more groups, one-way ANOVA
followed by Neuman-Keuls post-hoc test was used.
Spearman’s correlation was used to calculate the correlationsTable 1 Clinical characteristics of patients
Characteristics Control (n = 40) SAP
Age (years) 62.6 ± 7.9 61.9
Sex (male/female) 29/11 44/1
Hypertension, n (%) 22 (55) 34 (5
Diabetes, n (%) 6 (15) 20 (2
Smoking, n (%) 14 (35) 26 (4
BMI (Kg/m2) 23. 2 ± 3.9 24.8
TC (mmol/L) 4.52 ± 0.99 4.09
TG (mmol/L) 1.68 ± 1.75 1.84
LDL-C (mmol/L) 2.71 ± 0.87 2.38
HDL-C (mmol/L) 1.20 ± 0.34 1.11
GLU (mmol/L) 5.07 ± 0.9 5.67
Creatinine (μmol/L) 76.28 ± 14.97 88.2
CRP (mg/L) 1.49 ± 0.99 2.61
LVEF (%) 65.7 ± 5.0 62.6
LVEDD (mm) 46.7 ± 3.2 48.1
Gensini score 0 44.0
Medications, n (%)
Aspirin 6 (15) 24 (4
β-blocker 6 (15) 22 (3
ACEI/ARB 10 (25) 22 (3
CCB 16 (40) 32 (5
Statin 9 (22.5) 22 (5
Nitrate 9 (22.5) 9 (15
The data are given as the mean ± SD or number of patients. SAP: stable angina pec
cholesterol; TG: total triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C
ejection fraction; LVEDD: left ventricular end-diastolic dimension; ACEI: angiotensin-
channel blocker.
*P < 0.05 vs. control.between the plasma chemerin levels and the other mea-
sured parameters. To identify the independent predictors
of the presence of ACS, simple linear regression analyses
were firstly performed and the candidate variables entered
in the model included age, sex, BMI, hypertension, dia-
betes, smoking, lipid and lipoprotein fractions, fasting glu-
cose, creatinine, CRP, chemerin and adiponectin, and then
those variables exhibited a trend (p < 0.05) toward an asso-
ciation with the presence of ACS were entered in binary
logistic regression analyses. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated. In all of the
tests, a value of P < 0.05 was considered to be statistically
significant.
Results
Clinical characteristics of the study population
The baseline characteristics of the four groups were
shown in Table 1. In the SAP group (n = 60), 44 were
men, and mean age was 61.9 ± 9.9 years. In the UAP group
(n = 60), 37 were men, and mean age was 60.6 ± 9.9 years.(n = 60) UAP (n = 60) AMI (n = 60)
± 9.9 60.6 ± 9.9 62.9 ± 10.3
6 37/23 41/19
8) 38 (61.3) 32 (61.2)
8) 14 (38.7) 20 (37.3)
0) 23 (48) 28 (35.8)
± 3.0* 25.8 ± 2.7* 25.9 ± 2.6*
± 0.95 4.53 ± 1.19 4.40 ± 0.86
± 1.04 1.94 ± 1.61 1.82 ± 1.42
± 0.81 2.69 ± 1.16 2.71 ± 0.78
± 0.41 1.09 ± 0.37 0.94 ± 0.26*
± 2.03 6.22 ± 2.67 6.78 ± 2.91*
4 ± 23.03* 82.51 ± 20.29* 87.77 ± 35.23*
± 4.04 4.14 ± 4.09* 7.53 ± 7.08*
± 8.5 56.9 ± 12.5* 48.5 ± 10.4*
± 3.7 51.5 ± 7.6* 52.7 ± 5.5*
± 30.2* 52.0 ± 28.4* 61.9 ± 34.5*
0) 23 (38.3) 25 (41.7)
6.7) 26 (43.3) 30 (50)
6.7) 26 (43.3) 21 (35)
3.3) 28 (46.7) 26 (43.3)
2) 21 (35) 20 (33.3)
) 16 (26.7) 17 (28.3)
toris; UAP: unstable angina pectoris; AMI: acute myocardial infarction; TC: total
: high-density lipoprotein cholesterol; GLU: fasting glucose; LVEF: left ventricular
converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: Calcium
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was 62.9 ± 10.3 years. In the control group (n = 40), 29
were men, and mean age was 62.6 ± 7.9 years.
No significant differences in age, sex, history of hyper-
tension, diabetes or smoking were observed among the
four groups. BMI, creatinine, CRP, LVEDD, and the
Gensini score were significantly higher in the UAP and
AMI groups than in the control group; in contrast, the
LVEF in the UAP and AMI groups was lower than that
of the control group (Table 1).Plasma adipokines analysis
As shown in Table 2 and Figure 1, the plasma chemerin
levels in patients with CAD, specifically patients in the
AMI and UAP groups but not patients in the SAP
group, were significantly increased compared to those of
the control group. In addition, the plasma chemerin
levels in the AMI and UAP groups were significantly in-
creased compared to those in the SAP group. Further,
the plasma adiponectin levels in patients with CAD, in-
cluding the AMI and UAP groups, were significantly re-
duced compared to those in the control group. In
addition, the plasma adiponectin levels in the AMI
group but not the UAP group were significantly de-
creased compared to those in the SAP group (Figure 1).
A correlation analysis demonstrated that plasma chemerin
levels were weakly negatively correlated with plasma adi-
ponectin levels (r = -0.16, P = 0.011) (Figure 1).
We analyzed whether the levels of chemerin and adipo-
nectin changed with traditional risk factors, such as sex,
hypertension, diabetes, and smoking. As shown in Table 2,
the circulating chemerin and adiponectin levels exhibitedTable 2 Plasma levels of chemerin and adiponectin in
each groups and traditional risk factors
No. Chemerin (ng/ml) Adiponectin (μg/ml)
Control 40 37.55 ± 7.42 8.34 ± 3.06
CAD 180 51.95 ± 18.13** 5.95 ± 3.13**
SAP 60 42.85 ± 11.60 6.74 ± 3.01
UAP 60 53.62 ± 14.65**,## 6.19 ± 3.14**
AMI 60 59.38 ± 22.46**,## 4.92 ± 3.02**,##
Male 151 47.99 ± 18.12 6.29 ± 3.09
Female 69 52.26 ± 16.10 6.59 ± 3.59
Hypertension 126 50.10 ± 16.19 6.61 ± 3.12
Normotension 94 48.30 ± 16.19 6.08 ± 3.41
Diabetes 60 50.89 ± 22.02 6.54 ± 3.25
Non-diabetes 160 48.75 ± 15.65 6.33 ± 3.26
Smoking 91 47.24 ± 16.43 5.79 ± 2.97
Non-smoking 129 50.81 ± 18.28 6.80 ± 3.38
Note: The data are given as the mean ± SD. **P < 0.01 vs. Control, ##P < 0.01
vs. SAP.no significant differences in association with these trad-
itional risk factors among all of the participants.
In addition, the plasma chemerin and adiponectin
levels of all participants were summarized according to
medication in the present study. The results demonstrated
that the administration of aspirin, β-blocker, angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin recep-
tor blocker (ARB), calcium channel blocker (CCB), statin
and nitrate had no significant effects on plasma levels of
chemerin and adiponectin (Table 3).
Relationship between plasma adipokine concentrations
and the presence of ACS
Because plasma levels of chemerin and adiponectin were
significantly regulated in patients with ACS, we analyzed
the correlation between the plasma chemerin and adipo-
nectin levels and clinical parameters in ACS. The results
showed that plasma levels of chemerin were positively
correlated with CRP and LVEDD but negatively correlated
with the LVEF, and the plasma levels of adiponectin were
positively correlated with the LVEF but negatively corre-
lated with TC, LDL-C, CRP and LVEDD (Table 4 and
Figure 2). Although significant correlations between che-
merin (r = 0319, P = 0.013), adiponectin (r = -0.262, P =
0.043) and BMI were found in patients with SAP, neither
chemerin (r = 0.164, P = 0.075) nor adiponectin (r = -0.100,
P = 0.275) was correlated with BMI in patients with ACS.
In addition, although significant correlations between che-
merin (r = 0.279, P = 0.031), adiponectin (r = -0.486, P =
0.000) and the Gensini score were found in SAP, neither
chemerin (r = 0.098, P = 0.286) nor adiponectin (r = -0.074,
P = 0.415) was correlated with the Gensini coronary score
in ACS. However, there were no correlations between the
levels of chemerin and adiponectin and the other parame-
ters including age, TG, HDL-C, fasting glucose and
creatinine.
Simple linear regression and binary logistic regression
analyses
To determine the independent predictors of the pres-
ence of ACS, we performed simple linear regression and
binary logistic regression analyses. Simple logistic regres-
sion analysis demonstrated that fasting glucose, TC,
HDL-C, LDL-C, CRP, adiponectin, and chemerin exhib-
ited a trend (P < 0.05) toward an association with the
presence of ACS. A binary logistic regression analyses
was then performed using a model in which variables
were included fasting glucose, TC, HDL-C, LDL-C, CRP,
adiponectin, and chemerin. The results demonstrated that
glucose (OR 1.288, 95% CI 1.064 to 1.558; p = 0.009), CRP
(OR 1.205, 95% CI 1.070 to 1.357; P = 0.002), adiponectin
(OR 0.871, 95% CI 0.776 to 0.970; P = 0.018), and che-
merin (OR 1.103, 95% CI 1.065 to 1.142; P = 0.001) were
independently associated with the presence of ACS.
Figure 1 The plasma adipokine concentrations in each group. A: The plasma chemerin levels in patients with AMI and UAP were
significantly increased compared to those of the control and SAP groups. B: The plasma adiponectin levels in patients with AMI and UAP were
significantly reduced compared to those of the control group. C: The levels of chemerin were negatively correlated with the levels of adiponectin
(r = 0.161, P = 0.017).
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Similar to our previous study [17], the present results
demonstrated that plasma levels of adiponectin were sig-
nificantly reduced in ACS patients compared to the con-
trol group, and that adiponectin was independently
associated with the presence of ACS. Furthermore, the
results also demonstrated that plasma levels of chemerin
were significantly increased in patients with UAP and
AMI compared to the control and SAP groups, and
negatively correlated with plasma adiponectin levels. In
addition, the binary logistic regression analyses demon-
strated that a high level of chemerin was independently
associated with the presence of ACS. Although a number
of studies reported a high level of circulating chemerin in
CAD [31-33], our present study found for the first time
that plasma chemerin may be a novel biomarker of ACS
but not of SAP, providing a novel insight into understand
the complex relationship between chemerin and CAD.
These results were consistent with another study in whichTable 3 Plasma levels of chemerin and adiponectin in all
patients according to medication
Medication No. Chemerin (ng/ml) Adiponectin (μg/ml)
Aspirin Yes 78 51.15 ± 18.26 5.82 ± 3.04
No 142 48.28 ± 17.18 6.69 ± 3.33
β-blocker Yes 84 50.34 ± 16.80 5.94 ± 2.74
No 136 48.71 ± 18.09 6.65 ± 3.51
ACEI/ARB Yes 79 48.79 ± 15.95 6.01 ± 3.08
No 141 49.63 ± 18.49 6.59 ± 3.32
CCB Yes 103 49.72 ± 16.77 6.57 ± 3.34
No 117 48.99 ± 18.34 6.22 ± 3.17
Statin Yes 72 48.93 ± 19.48 6.63 ± 3.74
No 148 49.53 ± 16.66 6.27 ± 2.99
Nitrate Yes 51 48.59 ± 13.17 6.40 ± 2.89
No 169 49.56 ± 18.75 6.38 ± 3.36
Note: The data are given as the mean ± SD.there were no difference in chemerin levels between
asymptomatic type 2 diabetic patients with CAD and
without CAD, suggesting that chemerin is not a biomarker
of patients with stable CAD [36].
Chemerin was initially identified from psoriatic skin
lesions [26], and was subsequently proved to be a func-
tional protein in human inflammatory fluids that served
as the ligand of ChemR23 [27]. Both chemerin and
ChemR23 are expressed at their highest levels in white
adipose tissue, and the chemerin/ChemR23 axis plays a
critical role in adipogenesis and adipocyte metabolism
[28]. Beyond these observations, accumulating experi-
mental evidence established a pleiotropic role for che-
merin in diverse biological processes including the
regulation of immune response, inflammation, insulin
resistance and angiogenesis [29]. Data showed that che-
merin promotes the migration of macrophage and im-
mature dendritic cell [27]. It is well-known that a
macrophage-to-foam cell switch elicits the initiation andTable 4 Correlations between chemerin, adiponectin and
other measured parameters in ACS
Characteristics Chemerin (ng/ml) Adiponectin (μg/ml)
Age (years) 0.11 -0.07
BMI (Kg/m2) 0.16 -0.10
TC (mmol/L) 0.10 -0.25**
TG (mmol/L) 0.09 0.11
LDL-C (mmol/L) 0.10 -0.32**
HDL-C (mmol/L) 0.05 0.02
GLU (mmol/L) 0.15 -0.10
Creatinine (μmol/L) 0.11 -0.13
CRP (mg/L) 0.29** -0.33**
LVEF (%) -0.45** 0.53**
LVEDD (mm) 0.27** -0.30**
Gensini score 0.10 -0.07
**P < 0.01.
Figure 2 Correlations between chemerin, adiponectin and other measured parameters in ACS. A: Plasma levels of chemerin were
positively correlated with CRP in patients with ACS. B: Plasma levels of adiponectin were negatively correlated with CRP in patients with ACS.
C: Plasma levels of chemerin were negatively correlated with LVEF in patients with ACS. D: Plasma levels of adiponectin were positively correlated
with LVEF in patients with ACS. E: Plasma levels of chemerin were positively correlated with LVEDD in patients with ACS. F: Plasma levels of
adiponectin were negatively correlated with LVEDD in patients with ACS.
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tion of macrophages induce the rupture of plaque and
the thrombus formation in advanced atherosclerosis
[1-4]. Therefore, chemerin may be involved in different
stages of atherosclerosis through regulating the migra-
tion of macrophage. In contrary, accumulating evidence
demonstrated that adiponectin not only suppresses foam
cell transformation but also inhibits the pro-coagulant
activity of macrophage [37]. In the present study, a high
level of chemrin and a low level of adiponectin were
detected in ACS, suggesting the imbalance of pro-
inflammatory/anti-inflammatory adipokines may be as-
sociated with the presence of ACS by regulation theactivity of macrophage. However, this is still a hypoth-
eses which need be clarified in the future.
A large number of clinical studies demonstrated that
elevated levels of circulating chemerin were associated
with the onset of many traditional risk factors of CAD,
such as sex [38], hypertension [39], and diabetes [40].
However, those findings were not observed in the
present study. Data from previous studies revealed that
medication use effectively regulates the secretion of che-
merin and adiponectin [16,41]. More recently, a CAD
case–control study found that plasma chemerin levels
were significantly higher in CAD patients who were not
treated with aspirin than in patients treated with aspirin
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effect of medication on chemerin and adiponectin. The
results revealed no difference in circulating levels of che-
merin and adiponectin based on aspirin, β-blocker, ACEI
or ARB, CCB, statin, or nitrate use.
Bioactive adipokines are secreted by adipose tissue and
the list of adipokines has reached hundreds of factors.
Accumulating evidence established that obesity, charac-
terized by a condition of excess adipose tissue, resulted
in the imbalance of pro-inflammatory/anti-inflammatory
adipokines, and therefore deeply involved in the devel-
opment of atherosclerotic disease [6,42,43]. The point
that adipokine is the bridge between obesity and athero-
sclerosis is no longer controversial. In the present study,
we found positive correlation between chemerin and
BMI, and inverse correlation between adiponectin and
BMI in patients with SAP, which was consistent with
many previous studies [22,32,33]. However, neither che-
merin nor adiponectin was correlated with BMI in pa-
tients with ACS, suggesting the regulation in adipokine
production is more complicated in ACS.
Numerous studies demonstrated that circulating che-
merin levels were correlated with lipid and lipoprotein
fractions, fasting glucose, and various markers of inflam-
mation [31-33,40]. Although no correlations between che-
merin and lipid and lipoprotein fractions, fasting glucose,
and creatinine were observed in the present study, the
results demonstrated that CRP, which is an established
marker of inflammation, was positively correlated with
chemerin but negatively correlated with adiponectin, sug-
gesting that inflammation may be the bridge between adi-
pokines and ACS. Correlation analyses also demonstrated
that increased chemerin levels were positively correlated
with LVEDD but negatively correlated with LVEF and that
reduced adiponectin levels were positively correlated with
LVEF but negatively correlated with LVEDD in ACS. It is
well-known that ACS patients with severe systemic in-
flammation and impaired cardiac function are at higher
risk for death and future ischemic events. Accumulating
evidence also demonstrated that increased circulating adi-
ponectin levels in ACS were independently associated with
a higher risk of recurrent cardiovascular events including
death, myocardial infarction and heart failure [16]. There-
fore, whether circulating chemerin levels in ACS are
associated with a higher risk of recurrent cardiovascular
events should be investigated in the future.
Although the levels of adiponectin in the complex lesion
group and the simple lesion group were significantly lower
than those of the control group in our previous study, no
differences were observed between the complex and sim-
ple lesion groups [17]. In the present study, the Gensini
score was used to assess the severity of coronary stenosis
in CAD patients. Although significant correlations be-
tween the two adipokines and the Gensini score werefound in patients with SAP, neither chemerin nor adipo-
nectin was correlated with the Gensini coronary score in
patients with ACS. Our colleagues Gao et al. showed no
correlations between circulating chemerin or adiponectin
and the Gensini coronary score in a previous study [44],
while another study performed by Yan et al. found that
chemerin levels were associated with the Gensini score
even after adjusting for age, sex, and other established risk
factors of CAD [31]. We speculate that enrolled patients
with different clinical types of CAD may contribute to this
discrepancy. Yan et al. may enroll majority patients with
stable CAD in their study, while Gao et al. may enroll ma-
jority patients with ACS.
Conclusions
In conclusion, our study presented for the first time novel
data that reveal increased plasma chemerin levels in ACS
but not in SAP. More importantly, we found that
increased plasma chemerin levels were independently as-
sociated with the presence of ACS. Thus, circulating che-
merin may serve as a novel biomarker of ACS but not of
SAP. However, the present study has some limitations.
There has been no follow-up with these ACS patients to
assess the short- and long-term prognostic significance of
chemerin levels, which should be investigated in the fu-
ture. The relationship between chemerin and cardiac func-
tion also should be investigated in experimental study.
Abbreviations
ACS: Acute coronary syndromes; ACEI: Angiotensin-converting enzyme inhibitor;
AMI: Acute myocardial infarction; ARB: Angiotensin receptor blocker;
CCB: Calcium channel blocker; CAD: Coronary artery disease; CRP: C-reactive
protein; GLU: Fasting glucose; HDL-C: High-density lipoprotein cholesterol;
LDL-C: Low-density lipoprotein cholesterol; LVEDD: Left ventricular end-diastolic
dimension; LVEF: Left ventricular ejection fraction; SAP: Stable angina pectoris;
TC: Total cholesterol; TG: Total triglycerides; UAP: Unstable angina pectoris.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YZL, ZSL, KWY, YYL, ZF, LL and YS participated in the data acquisition. YZL
and ZSL participated in the design of the study and performed the statistical
analysis. CC and MC participated in the statistical analysis. YJZ, QWJ and QTZ
conceived of the study, and participated in its design and coordination and
draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the National Natural Science Foundation of China
(No. 81160045 and 81270285), the Beijing Municipal High-Level Talent Foundation
Of Health System (No. 2011-1-5), Beijing Municipal Administration of Hospitals
Clinical Medicine Development of Special Funding Support (Code: ZY201303) and
the National Key Clinical Speciality Construction Project.
Author details
1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical
University, Beijing Institute of Heart Lung and Blood Vessel Disease, The Key
Laboratory of Remodeling-related Cardiovascular Disease, Ministry of
Education, Beijing 100029, China. 2Department of Cardiology, The People’s
Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China.
3Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan 430022, China.
Ji et al. Cardiovascular Diabetology 2014, 13:145 Page 8 of 9
http://www.cardiab.com/content/13/1/145Received: 4 October 2014 Accepted: 9 October 2014
References
1. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E: Monocytes in coronary
artery disease and atherosclerosis where are we now? J Am Coll Cardiol
2013, 62:1541–1551.
2. Libby P: Mechanisms of acute coronary syndromes and their implications
for therapy. N Engl J Med 2013, 368:2004–2013.
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon
JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S,
Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de
Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro
JH, Farb A, Galis ZS, Jackson C, Jang IK, et al: From vulnerable plaque to
vulnerable patient: a call for new definitions and risk assessment
strategies: Part I. Circulation 2003, 108:1664–1672.
4. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW:
Multiple complex coronary plaques in patients with acute myocardial
infarction. N Engl J Med 2000, 343:915–922.
5. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and
regulatory pathways. Physiol Rev 2006, 86:515–581.
6. Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN: Adipokines as mediators of
endothelial function and atherosclerosis. Atherosclerosis 2013,
227:216–221.
7. Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA: Potential
biomarkers of insulin resistance and atherosclerosis in type 2 diabetes
mellitus patients with coronary artery disease. Int J Endocrinol 2013,
2013:698567.
8. Asterholm IW, Rutkowski JM, Fujikawa T, Cho YR, Fukuda M, Tao C, Wang
ZV, Gupta RK, Elmquist JK, Scherer PE: Elevated resistin levels induce
central leptin resistance and increased atherosclerotic progression in
mice. Diabetologia 2014, 57:1209–1218.
9. Zhou F, Pan Y, Huang Z, Jia Y, Zhao X, Chen Y, Diao J, Wan Q, Cui X:
Visfatin induces cholesterol accumulation in macrophages through
up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones
2013, 18:643–652.
10. Wan Q, Cui X, Shao J, Zhou F, Jia Y, Sun X, Zhao X, Chen Y, Diao J, Zhang L:
Beijing ambient particle exposure accelerates atherosclerosis in ApoE
knockout mice by upregulating visfatin expression. Cell Stress Chaperones
2014, 19:715–724.
11. Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF: Cytokine imbalance in
acute coronary syndrome. Curr Opin Pharmacol 2004, 4:166–170.
12. Liu SW, Qiao SB, Yuan JS, Liu DQ: Association of plasma visfatin levels
with inflammation, atherosclerosis and acute coronary syndromes (ACS)
in humans. Clin Endocrinol (Oxf ) 2009, 71:202–207.
13. Basati G, Razavi AE, Abdi S, Sarrafzedegan N: Association of plasma leptin,
homocysteine and nitric oxide levels with the presence and unstability
of coronary artery disease. Biomark Med 2014, 8:405–412.
14. Huang CL, Wu YW, Wu CC, Lin L, Wu YC, Hsu PY, Jong YS, Yang WS: Association
between serum adipocyte fatty-acid binding protein concentrations, left
ventricular function and myocardial perfusion abnormalities in patients with
coronary artery disease. Cardiovasc Diabetol 2013, 12:105.
15. van Stijn CM, Kim J, Barish GD, Tietge UJ, Tangirala RK: Adiponectin
expression protects against angiotensin II-mediated inflammation and
accelerated atherosclerosis. PLoS One 2014, 9:e86404.
16. Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N,
Cannon CP, Morrow DA, TIMI Study Group: Assessment of adiponectin
and the risk of recurrent cardiovascular events in patients presenting
with an acute coronary syndrome: observations from the Pravastatin Or
atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial
Infarction 22 (PROVE IT-TIMI 22). Am Heart J 2011, 161:1147–1155.
17. Cheng M, Hashmi S, Mao X, Zeng QT: Relationships of adiponectin and
matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1
ratio with coronary plaque morphology in patients with acute coronary
syndrome. Can J Cardiol 2008, 24:385–390.
18. Rizk NM, El-Menyar A, Marei I, Sameer M, Musad T, Younis D, Farag F, Basem
N, Al-Ali K, Al Suwaidi J: Association of adiponectin gene polymorphism
(+T45G) with acute coronary syndrome and circulating adiponectin
levels. Angiology 2013, 64:257–265.
19. Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, Sawada T,
Hirata K, Yokoyama M: Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in
patients with acute coronary syndrome. Am J Cardiol 2008, 101:1–7.
20. Mittal A, Gupta MD, Meennahalli Palleda G, Vyas A, Tyagi S: Relationship of
plasma adiponectin levels with acute coronary syndromes and coronary
lesion severity in north Indian population. ISRN Cardiol 2013, 2013:854815.
21. Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, Hong BK, Rim SJ, Kwon
HM: Usefulness of metabolic syndrome score in the prediction of
angiographic coronary artery disease severity according to the presence
of diabetes mellitus: relation with inflammatory markers and adipokines.
Cardiovasc Diabetol 2013, 12:140.
22. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T,
Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K,
Yoshikawa J: Implications of plasma concentrations of adiponectin in
patients with coronary artery disease. Heart 2004, 90:528–533.
23. Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D: Adiponectin levels and
risk of coronary heart disease: a meta-analysis of prospective studies. Am
J Med Sci 2013, 345:455–461.
24. Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G, Lundman
P: Low plasma adiponectin concentration is associated with myocardial
infarction in young individuals. J Intern Med 2010, 268:194–205.
25. Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo
Oh S: Association between adiponectin levels and coronary heart
disease and mortality: a systematic review and meta-analysis. Int J
Epidemiol 2013, 42:1029–1039.
26. Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic
M, Chandraratna RA: Tazarotene-induced gene 2 (TIG2), a novel retinoid-
responsive gene in skin. J Invest Dermatol 1997, 109:91–95.
27. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I,
Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S,
Vassart G, Parmentier M, Communi D: Specific recruitment of antigen-
presenting cells by chemerin, a novel processed ligand from human
inflammatory fluids. J Exp Med 2003, 198:977–985.
28. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD,
Muruganandan S, Sinal CJ: Chemerin, a novel adipokine that regulates
adipogenesis and adipocyte metabolism. J Biol Chem 2007,
282:28175–28188.
29. Roman AA, Parlee SD, Sinal CJ: Chemerin: a potential endocrine link
between obesity and type 2 diabetes. Endocrine 2012, 42:243–251.
30. Yamawaki H, Kameshima S, Usui T, Okada M, Hara Y: A novel
adipocytokine, chemerin exerts anti-inflammatory roles in human
vascular endothelial cells. Biochem Biophys Res Commun 2012,
423:152–157.
31. Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G:
The association of serum chemerin level with risk of coronary artery
disease in Chinese adults. Endocrine 2012, 41:281–288.
32. Xiaotao L, Xiaoxia Z, Yue X, Liye W: Serum chemerin levels are associated
with the presence and extent of coronary artery disease. Coron Artery Dis
2012, 23:412–416.
33. Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, Chen L, Hong H: Elevated serum
chemerin levels are associated with the presence of coronary artery
disease in patients with type 2 diabetes. Clin Lab 2012, 58:539–544.
34. Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M: Low dose
aspirin is associated with plasma chemerin levels and may reduce
adipose tissue inflammation. Atherosclerosis 2014, 235:256–262.
35. Gensini GG: A more meaningful scoring system for determining the
severity of coronary heart disease. Am J Cardiol 1983, 51:606.
36. Kim HM, Lee BW, Song YM, Kim WJ, Chang HJ, Choi DH, Yu HT, Kang E, Cha
BS, Lee HC: Potential association between coronary artery disease and
the inflammatory biomarker YKL-40 in asymptomatic patients with type
2 diabetes mellitus. Cardiovasc Diabetol 2012, 11:84.
37. Okamoto Y, Ishii S, Croce K, Katsumata H, Fukushima M, Kihara S, Libby P,
Minami S: Adiponectin inhibits macrophage tissue factor, a key trigger of
thrombosis in disrupted atherosclerotic plaques. Atherosclerosis 2013,
226:373–377.
38. Venojärvi M, Wasenius N, Manderoos S, Heinonen OJ, Hernelahti M, Lindholm
H, Surakka J, Lindström J, Aunola S, Atalay M, Eriksson JG: Nordic walking
decreased circulating chemerin and leptin concentrations in middle-aged
men with impaired glucose regulation. Ann Med 2013, 45:162–170.
39. Meric M, Soylu K, Avci B, Yuksel S, Gulel O, Yenercag M, Coksevim M, Uzun
A: Evaluation of plasma chemerin levels in patients with non-dipper
blood pressure patterns. Med Sci Monit 2014, 20:698–705.
Ji et al. Cardiovascular Diabetology 2014, 13:145 Page 9 of 9
http://www.cardiab.com/content/13/1/14540. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S,
Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C: Systemic
chemerin is related to inflammation rather than obesity in type 2
diabetes. Clin Endocrinol (Oxf ) 2010, 72:342–348.
41. Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D’Angelo A, Maffioli P:
Results from a 12 months, randomized, clinical trial comparing an
olmesartan/amlodipine single pill combination to olmesartan and
amlodipine monotherapies on blood pressure and inflammation. Eur J
Pharm Sci 2014, 1:26–33.
42. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K: Adipocytokines in
relation to cardiovascular disease. Metabolism 2013, 62:1513–1521.
43. Nakamura K, Fuster JJ, Walsh K: Adipokines: a link between obesity and
cardiovascular disease. J Cardiol 2014, 63:250–259.
44. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H:
Association of chemerin mRNA expression in human epicardial adipose
tissue with coronary atherosclerosis. Cardiovasc Diabetol 2011, 10:87.
doi:10.1186/s12933-014-0145-4
Cite this article as: Ji et al.: Chemerin is a novel biomarker of acute
coronary syndrome but not of stable angina pectoris. Cardiovascular
Diabetology 2014 13:145.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
